Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease

Biomarkers

Volumn 14, Issue 4, 2009, Pages 250-257

  Peters, John H ^a,b   Greasby, Tammy ^a   Lane, Nancy ^a   Woolf, Anthony ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

Alternative splicing; Biomarkers; Fibronectins; Vasculitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRONECTIN; ISOPROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE MARKER; FEMALE; HIGH RISK PATIENT; HUMAN; INFLAMMATORY DISEASE; MALE; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; RETROSPECTIVE STUDY; VASCULITIS; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; VASCULITIS; VON WILLEBRAND FACTOR;

EID: 68549140330     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902836032     Document Type: Article

References (35)

1. Amrani DL, Mauzy-Melitz D, Mosesson MW. (1986). Effect of hepatocyte- stimulating factor and glucocorticoids on plasma fibronectin levels. Biochem J 238:365-371
2. Blake GJ, Ridker PM. (2003). C-reactive protein: A surrogate risk marker or mediator of atherothrombosis? Am J Physiol Regul Integr Comp Physiol 285:R1250-2.
3. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A. (2004). Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35:1671-1676
4. Clark RA, Quinn JH, Winn HJ, Lanigan JM, Dellepella P, Colvin RB. (1982). Fibronectin is produced by blood vessels in response to injury. J Exp Med 156:646-651
5. Dubin D, Peters JH, Brown LF, Logan B, Kent KC, Berse B, Berven S, Cercek B, Sharifi BG, Pratt RE, et al. (1995). Balloon catheterization induced arterial expression of embryonic fibronectins. Arterioscler Thromb and Vasc Biol 15:1958-1967
6. Fijnheer R, Frijns CJ, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK. (1997). The origin of P-selectin as a circulating plasma protein. Thromb Haemost 77:1081-1085
7. Frijns CJ, Rinkel GJ, Castigliego D, Van Gijn J, Sixma JJ, Fijnheer R. (2002). Endothelial cell activation after subarachnoid hemorrhage. Neurosurgery 50:1223-9; discussion 1229-30.
8. Fyrand O, Munthe E, Solum NO. (1978). Studies on cold insoluble globulin. I Concentrations in citrated plasma in rheumatic disorders. Ann Rheum Dis 37:347-350
9. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. (1997). Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 123:285-296
10. Hynes R. (1990). Fibronectins. New York: Springer-Verlag, Inc.
11. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. (1994). Expression of variant fibronectins in wound healing: Cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127:2037-2048
12. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. (1994). Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192
13. Krishnamurthy A, Naguwa SM, Cheema GS, Gershwin ME. (2006). Vasculitis: Contemporary perspectives. Comp Ther 32:118-126
14. Lockwood CJ, Peters JH. (1990). Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 162:358-362
15. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Adu D. (1994). Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671-678
16. Nickeleit V, Zagachin L, Nishikawa K, Peters JH, Hynes RO, Colvin RB. (1995). Embryonic fibronectin isoforms are synthesized in crescents in experimental autoimmune glomerulonephritis. Am J Pathol 147:965-978
17. Paul JI, Schwarzbauer JE, Tamkun JW, Hynes RO. (1986). Cell-typespecific fibronectin subunits generated by alternative splicing. J Biol Chem 261:12258-12265
18. Peters JH, Chen GE, Hynes RO. (1996). Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes Commun 4:127-148
19. Peters JH, Ginsberg MH, Bohl BP, Sklar LA, Cochrane CG. (1986). Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. J Clin Invest 78:1596-1603
20. Peters JH, Ginsberg MH, Case CM, Cochrane CG. (1988). Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. Am Rev Respir Dis 138:167-174
21. Peters JH, Loredo GA, Chen G, Maunder R, Hahn TJ, Willits NH, Hynes RO. (2003). Plasma levels of fibronectin bearing the alternatively spliced EIIIB segment are increased after major trauma. J Lab Clin Med 141:401-410
22. Peters JH, Maunder RJ, Woolf AD, Cochrane CG, Ginsberg MH. (1989). Elevated plasma levels of ED1+ ('cellular') fibronectin in patients with vascular injury. J Lab Clin Med 113:586-597
23. Peters JH, Sporn LA, Ginsberg MH, Wagner DD. (1990). Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type III homology (ED1). Blood 75:1801-1808
24. Peters JH, Trevithick JE, Johnson P, Hynes RO. (1995). Expression of the alternatively spliced EIIIB segment of fibronectin. Cell Adhes Commun 3:67-89.
25. Pick-Kober KH, Munker D, Gressner AM. (1986). Fibronectin is synthesized as an acute phase reactant in rat hepatocytes. J Clin Chem Clin Biochem 24:521-528
26. Satoi S, Hiramatsu Y, Kitade H, Kwon AH, Matsui K, Miyashita K, Sakashita E, Sekiguchi K, Takahashi H, Kamiyama Y. (1999). Different responses to surgical stress between extra domain A+ and plasma fibronectins. Clin Exp Pharmacol Physiol 26:225-229
27. Schwarzbauer JE. (1991). Alternative splicing of fibronectin: Fhree variants, three functions. Bioessays 13:527-533
28. Sikkema JM, Franx A, Fijnheer R, Nikkels PG, Bruinse HW, Boomsma F. (2002). Semicarbazide-sensitive amine oxidase in pre-eclampsia: No relation with markers of endothelial cell activation. Clin Chim Acta 324:31-38
29. Tamkun JW, Hynes RO. (1983). Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 258:4641-4647
30. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. (2004). Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104:11-18.
31. ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. (1990). C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. J Rheumatol 17:1642-1648
32. Uddhammar AC. (2000). Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 18:S32-3.
33. Vartio T, Laitinen L, Narvanen O, Cutolo M, Thornell LE, Zardi L, Virtanen I. (1987). Differential expression of the ED sequencecontaining form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci 88:419-430
34. Voskuyl AE, Emeis JJ, Hazes JM, van Hogezand RA, Biemond I, Breedveld FC. (1998). Levels of circulating cellular fibronectin are increased in patients with rheumatoid vasculitis. Clin Exp Rheumatol 16:429-434
35. Woolf AD, Wakerley G, Wallington TB, Scott DG, Dieppe PA. (1987). Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis 46:441-447